Advanced Development of Nitazoxanide Administered Alone or In Combination with Oseltamivir for Treatment of Acute Uncomplicated Influenza Virus Infection in Adults and Pediatric Patients at Least 12 Years of Age
Award Notice Posted
- Solicitation number
- Not on record
- Agency
-
Immediate Office of the Secretary
Department of Health and Human Services
- Awarded
- to Romark Laboratories, L.C.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSO100201300004C Federal contract award
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
This announcement is for the award of a Cost Plus Fixed Fee (CPFF) type Research and Development contract to Romark Laboratories for Advanced Development of Nitazoxanide Administered Alone or In Combination with Oseltamivir for Treatment of Acute Uncomplicated Influenza Virus Infection in Adults and Pediatric Patients at Least 12 Years of Age under the procedures for the subject Broad Agency Announcement (BAA). This contract outlines the work required to develop Nitazoxanide, a broad spectrum antiviral therapeutic, for treatment of influenza virus infections in adults and pediatric patients at least 12 years of age.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity